Marie Couldwell
Endocrinology, Diabetes & Metabolism · Salt Lake City, UTNPI 1083793558
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,260 and has fallen 98.4% since, to $20 in 2022. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in UT, where the typical reported total is $3,842.
Across 240 payments — averaging $14.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$508
- Boehringer Ingelheim$331
- Insulet Corporation$270
- Lilly USA, LLC$223
- AbbVie$219
- Merck$219
- plus $2K from 20 others
What the payments were for
- Food & beverage$3,446100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $508 |
| Boehringer Ingelheim | 18 | $331 |
| Insulet Corporation | 17 | $270 |
| Lilly USA, LLC | 17 | $223 |
| AbbVie | 16 | $219 |
| Merck | 14 | $219 |
| Amgen | 10 | $198 |
| Dexcom, Inc. | 15 | $192 |
| Abbott | 19 | $186 |
| Corcept Therapeutics | 9 | $125 |
| Xeris Pharmaceuticals, Inc. | 7 | $119 |
| Tandem Diabetes Care, Inc. | 6 | $106 |
| Antares Pharma, Inc. | 7 | $96 |
| Medtronic(2 entities) | 6 | $92 |
| AstraZeneca | 7 | $90 |
| Ipsen Biopharmaceuticals, Inc | 4 | $77 |
| Vistapharm, Inc. | 5 | $74 |
| Sanofi-aventis U.S. LLC | 6 | $72 |
| Mannkind Corporation | 4 | $57 |
| Recordati_rare_diseases_inc. | 2 | $46 |
| Pfizer | 3 | $45 |
| Radius Health, Inc. | 2 | $40 |
| Strongbridge US Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Companion Medical, Inc. | 1 | $12 |
How this compares
$3,446 in reported general payments places this provider in the 45th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 108 | $169,356 |
| JardianceEmpagliflozin | 103 | $130,312 |
| MounjaroTirzepatide | 97 | $128,922 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $125,908 |
| TrulicityDulaglutide | 78 | $108,058 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $59,326 |
| Teriparatide | 11 | $26,786 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $24,921 |
| FarxigaDapagliflozin Propanediol | 21 | $23,586 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $23,100 |
| JanuviaSitagliptin Phosphate | 23 | $22,946 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $22,809 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $21,403 |
| Gvoke Hypopen 2-PackGlucagon | 29 | $20,687 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $20,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $223 | $248,406231 claims |
| Novo NordiskOzempic | $508 | $169,356108 claims |
| Boehringer IngelheimJardiance | $331 | $130,312103 claims |
| AstraZenecaFarxiga | $90 | $23,58621 claims |
| MerckJanuvia | $219 | $22,94623 claims |
| AbbVieSynthroid | $219 | $1,14415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
Other endocrinology, diabetes & metabolism in Salt Lake City
- Eliot BrintonSalt Lake City$733K
- Alireza Falahati-NiniSalt Lake City$241K
- Shahzad AhmadSalt Lake City$25K
- Vishnu SundareshSalt Lake City$18K
- Bruce BradySalt Lake City$5K
- Barry BenowitzSalt Lake City$4K
- Kelsey DesalvoSalt Lake City$3K
- Sneha WagleSalt Lake City$257
- Javier Munoz BarreraSalt Lake City$160
- Ross HeinrichSalt Lake City$122
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.